Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate-to-severe Psoriasis Clear all
Completed Phase 3 Interventional Results available

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

NCT00115076
View directory record Official record
Conditions
Psoriasis
Interventions
Efalizumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06176768
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LY3972406, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

NCT01511315
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

NCT06108544
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TAK-279, Placebo, Apremilast
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NCT02203032
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

NCT00941031
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
AIN457, AIN457A, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT05364554
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Sacramento, California • Ocala, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

NCT06973291
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Zasocitinib, Deucravacitinib, Placebo to match zasocitinib, Placebo to match deucravacitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

NCT07801495
View directory record Official record
Conditions
Moderate to Severe Psoriatic Arthritis
Interventions
DDY391, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Memphis, Tennessee • Colleyville, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

NCT01043393
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.25% spray
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 4 Interventional

Community Based Trial for AMEVIVE®

NCT00168753
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

NCT00655564
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 29, 2026, 11:24 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708590
View directory record Official record
Conditions
Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Bakersfield, California • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01710046
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
(CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 1 Interventional

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

NCT01577550
View directory record Official record
Conditions
Psoriasis
Interventions
BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Burbank, California • Miami, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

NCT03431974
View directory record Official record
Conditions
Psoriasis
Interventions
LD-Aminopterin oral capsule, Placebo oral capsule
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

High Dose Risankizumab for Psoriasis

NCT05283135
View directory record Official record
Conditions
Psoriasis
Interventions
risankizumab
Drug
Lead sponsor
Oregon Medical Research Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632
View directory record Official record
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

NCT02074982
View directory record Official record
Conditions
Chronic Plaque Type Psoriasis
Interventions
AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 29, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

NCT03587194
View directory record Official record
Conditions
Psoriasis
Interventions
Otezla
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 29, 2026, 11:24 AM EDT